Exhibit
31.1





CERTIFICATION
PURSUANT TO RULE 13A-14 OR 15D-14 OF THE


SECURITIES
EXCHANGE ACT 1934,


AS
ADOPTED PURSUANT TO SECTION 302


OF THE
SARBANNES-OXLEY ACT OF 2002





I, James F. Mongiardo, certify
that:





1.  I
have reviewed the quarterly report for the quarter ending March 31, 2010 on Form
10Q of RegenoCELL Therapeutics, Inc.;





2.  Based
upon my knowledge, this quarterly report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this quarterly
report;





3.  Based
upon my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;





4.  I
am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) ) and
internal control over financial reporting (as defined in Exchange Act Rules
13a-15 (f) and 15d- 15 (f) ) for the registrant and have:





a.  designed such
disclosure controls and procedures, or caused such disclosure controls
and  procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to me by others within those entities, particularly
during the period in which this quarterly report is being prepared;





b. designed such internal control
over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted
accounting purposes;





c.  evaluated the
effectiveness of the registrant’s disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this
quarterly report based upon such evaluation; and





d.  disclosed in this
quarterly report any change in the registrant’s internal control over financial
reporting that occurred during the registrant’s most recent fiscal quarter that
has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and





5.  I
have disclosed, based on my most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of
registrant’s board of directors (or persons performing the equivalent
functions):





a.  all significant
deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect
the registrant’s ability to record, process, summarize and report financial
information; and





b.  any fraud, whether or not
material, that involves management or other employees who have a significant
role in the registrant’s internal control over financial reporting.





Dated:  June
11, 2010





By:  /s/ James F.
Mongiardo


James F.
Mongiardo


Chief
Executive Officer


and


Chief
Financial Officer